Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Brain/Spinal Cord Cancers

 

Depocyt-Methotrexate trial for Leptomeningeal Metastases (6954)
A Phase II Study of the Combination of High-dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients with Parenchymal and Leptomeningeal Metastases from Breast Cancer

Investigator: Maciej Mrugala, MD, PhD;   Conditions: Stage IV Breast Cancer, Central Nervous System Involvement/Metastases, Leptomeningeal Metastases, Recurrent Breast Cancer, Tumors Metastatic to Brain;    Status: Open;   Study ID: NCT00992602

Celldex Act-IV Vaccine Study for Newly Diagnosed Glioblastoma (UW11038)
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma

Investigator: Maciej Mrugala, MD, PhD;   Conditions: Brain Cancer; Glioblastoma Multiforme;    Status: Recruiting;   Study ID: NCT01480479

Celldex ReACT (UW12001)
A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma

Investigator: Maciej Mrugala, MD, PhD;   Conditions: Glioblastoma Multiforme;    Status: Recruiting;   Study ID: NCT01498328

NovoCure TTF Fields for Newly Diagnosed Glioblastoma (UW13003)
A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM

Investigator: Maciej Mrugala, MD, PhD;   Conditions: Glioblastoma Multiforme;    Status: Recruiting;   Study ID: NCT00916409

Bevacizumab w/wo Radiation Therapy for Recurrent Glioblastoma (RTOG-1205)
Randomized Phase II Trial Of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

Investigator: George E. Laramore, MD;   Conditions: Adult Glioblastoma;    Status: Recruiting;   Study ID: NCT01730950

Radiation Therapy With or Without Temozolomide for Anaplastic Glioma (RTOG 0834)
Phase III Trial On Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The CATNON Intergroup Trial

Investigator: George Laramore, MD, PhD;   Conditions: Brain and Central Nervous System Tumors;    Status: Recruiting;   Study ID: NCT00626990

Imaging Study 7754
Cellular Proliferation Using [18F] fluorothymidine (FLT) Positron Emission Tomography (PET) in Brain Tumors

Investigator: Janet Eary, MD;   Conditions: Brain Tumor;    Status: Recruiting

Imaging Study 21213
Assessing Brain Tumors with [18F] Fluoromisonidazole (FMISO) PET

Investigator: Janet Eary, MD;   Conditions: Brain Tumor;    Status: Recruiting

Imaging Study 7185
Distinguishing Recurrent Glioma From Post-Radiation Change: Can Advanced MRI Techniques Predict Outcome?

Investigator: James Fink, MD;   Conditions: High-grade Glioma;    Status: Recruiting

PLX3397 + Radiation Therapy + Temozolomide for Newly Diagnosed Glioblastoma (20131088)
An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma

Investigator: Marc Chamberlain, MD;   Conditions: Astrocytomas; Brain Cancer; Glioblastoma Multiforme; Glioma; Solid Tumors;    Status: Recruiting;   Study ID: NCT01790503

18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors (7754)
Cellular Proliferation Imaging Using [18F]fluorothymidine (FLT) Positron Emission Tomography (PET) in Brain Tumors

Investigator: Jason Rockhill;   Conditions: Brain Cancer; Central Nervous System (CNS); Solid Tumors;    Status: Recruiting;   Study ID: NCT02167204

ANG1005 for Recurrent High-Grade Glioma (20140010)
ANG1005-CLN-03: A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients with Recurrent High-Grade Glioma

Investigator: Marc Chamberlain, MD;   Conditions: Glioma, Glioblastoma, Brain Tumor, Recurrent;    Status: Recruiting;   Study ID: NCT01967810